Cardinal Health Rating Analysis
In the past five working days the company's share appreciate by 4.17% while on Monday the shares dropped by 1.34%.
On Monday, Cardinal Health shares dropped by 1.34% and were being traded at $82.27 as a decline was seen in the company's market capital. The trading session began at a share price of $83.21 and during the courses of the session, the company's share price hit a higher estimate of $84.185 and a lower end at $82.08.The volume of shares at the end of the session was 1,902,621 shares and the last trade was called at $82.27. The current market capital of the health care services company is at $26,932 million.
The outstanding shares of the pharmaceutical company are calculated to be 327,359,000 shares. During the last five trading days, the firm’s stock has appreciated by 4.17% but in the last four weeks it has lost 3.19% whereas during the past three month it has dropped by 6.12%.
In the short term, the healthcare firm’s stick price was probable to reach $98.75 while this consensus was agreed upon by 12 analysts the price target fluctuated from a higher end of $108 to a lower end of $91. The standard deviation was calculated at $5.64. The up/down ratio was calculated to be 0 as the block trade of $31.72 million in up sticks and $0 million in down sticks was observed.
Insider Trading was observed at Cardinal Health. Barrett George S, Chairman and the CEO of Cardinal Health, on August 20, 2015 at a share price of $83.08 unloaded 300,000 shares. This information was disclosed by the company to the Securities and Exchange Commission on a form 4 filing and the whole transaction was worth $24,924,000. Currently 0.3% of the company is Insider owned whereas Institutional investors own 87.7%. A change of -41.48% have been witnessed in the company in the total insider ownership in the past six weeks and -0.08% change has been seen in the institutional ownership of the company.
Analysts who have commented on the firm’s stock include Zacks and Evercore IS. According to the analysts at Evercore, the firm has received a rating of Hold which has been downgraded from a rating of Buy. Evercore shared these ratings on July 14, 2015. As for Zacks, investment research firm has ranked the company’s stock at 3. According to the 1-5 scale, the firm was ranked at 3 which indicated that it was at a rating of Hold. Average rating of 1.53 is given by 15 Wall Street Analysts out of which 2 analysts have given the company a rating of Buy while 10 and 3 analysts have given a rating of Strong buy and Hold respectively.